RESUMEN
Enzyme kinetics is the study of enzymatic catalytic rates in biochemical reactions. This topic is commonly taught to life science students in introductory biochemistry courses during their undergraduate education. Unlike most other biochemistry topics, which focus on visual structures of biomolecules and their processes, enzyme kinetics is explained primarily through abstract mathematical and two-dimensional graphical plots. However, these abstract/symbolic representations often make it difficult for students to relate the kinetic parameters to the underlying molecular system that is being described. In this article, we present the design and development of a web-based multimedia interactive learning tool, biomolecular interactive tutorials (BIOMINT) to help students better bridge the relationships between these abstract mathematical models and the molecular behaviors, interactions, and dynamics that produce kinetic phenomena. This learning tool can be accessed at https://bit.ly/biomint. © 2019 International Union of Biochemistry and Molecular Biology, 48(1):74-79, 2020.
Asunto(s)
Bioquímica/educación , Enzimas/metabolismo , Aprendizaje , Proyectos de Investigación , Estudiantes , Disciplinas de las Ciencias Biológicas , Humanos , Cinética , UniversidadesRESUMEN
Activating germline mutations of anaplastic lymphoma kinase (ALK) occur in most cases of hereditary neuroblastoma (NB) and the constitutively active kinase activity of ALK promotes cell proliferation and survival in NB. Therefore, ALK kinase is a potential therapeutic target for NB. In this study, we show that the novel ALK inhibitor alectinib effectively suppressed cell proliferation and induces apoptosis in NB cell lines with either wild-type ALK or mutated ALK (F1174L and D1091N) by blocking ALK-mediated PI3K/Akt/mTOR signaling. In addition, alectinib enhanced doxorubicin-induced cytotoxicity and apoptosis in NB cells. Furthermore, alectinib induced apoptosis in an orthotopic xenograft NB mouse model. Also, in the TH-MYCN transgenic mouse model, alectinib resulted in decreased tumor growth and prolonged survival time. These results indicate that alectinib may be a promising therapeutic agent for the treatment of NB.